Opthea Limited
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases.
Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak.
Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
Opthea is committed to improving vision in patients suffering with retinal eye diseases.
Contact Info:
Address: Level 1, 10 Wallace Avenue, Toorak, Melbourne, VIC 3142, AU
Website: www.opthea.com
Phone: 613 9826 0399